Figure 4.
Rejection as a consequence of anti-CTLA-4 treatment and a GM-CSF-expressing vaccine results in immunity to rechallenge. Mice were treated as in Fig. 3a. Six weeks after initial challenge with SM1, mice were rechallenged (arrow) on a separate, shaved area of the back with 2 × 105 SM1 cells. Tumor growth was monitored, and incidence is indicated in parentheses.